Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2/anti-CD3 bispecific antibody M802

A humanized bispecific antibody composed of a monovalent unit directed against the tumor-associated antigen (TAA) human epidermal growth factor 2 (HER2; ErbB2; HER-2) and a single chain unit directed against CD3 found on T lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-HER2/anti-CD3 bispecific antibody M802 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HER2 on HER2-expressing tumor cells. This activates and redirects CTLs to HER2-expressing tumor cells, which results in the CTL-mediated cell death of HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HER2 x CD3 bispecific antibody M802
Code name:M 802
M-802
M802
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search